References
1a
Daly JW.
Garraffo HM.
Spande TF. In The Alkaloids - Chemistry and Pharmacology
Vol. 43:
Cordell GA.
Academic Press;
San Diego:
1993.
p.185
1b
Daly JW.
Nat. Prod.
1998,
61:
162
1c
Daly JW.
Garraffo HM.
Spande TF. In Alkaloids - Chemical and Biological Perspectives
Vol. 13:
Pelletier SW.
Pergamon;
New York:
1999.
p.1
2
Bailey PD.
Millwood PA.
Smith PD.
Chem. Commun.
1998,
1915
3a
Kobayashi S.
Ishitani H.
Angew. Chem. Int. Ed.
1998,
37:
979
3b
Reding MT.
Buchwald SL.
J. Org. Chem.
1998,
63:
6344
4
Weymann M.
Pfrengle W.
Schollmeyer D.
Kunz H.
Synthesis
1997,
1151
5
Kunz H.
Pfrengle W.
Angew. Chem., Int. Ed. Engl.
1989,
28:
1067
6a
Kunz H.
Sager W.
Angew. Chem., Int. Ed. Engl.
1987,
26:
557
6b
Kunz H.
Sager W.
Schanzenbach D.
Decker M.
Liebigs Ann. Chem.
1991,
649
7a
Kunz H.
Pfrengle W.
J. Am. Chem. Soc.
1988,
110:
651
7b
Kunz H.
Pfrengle W.
Rück K.
Sager W.
Synthesis
1991,
1039
8a
Laschat S.
Kunz H.
Synlett
1990,
51
8b
Laschat S.
Kunz H.
J. Org. Chem.
1991,
56:
5883
9
Danishefsky S.
J. Am. Chem. Soc.
1974,
96:
7807
10
Weymann M.
Schultz-Kukula M.
Knauer S.
Kunz H.
Monatsh. Chem.
2002,
133:
571
11 Compoumd 6d: [a]D
25 +66.6 (c 1, CHCl3). 1H NMR (200 MHz, CDCl3): d = 6.90 (d, 1 H, J
H-6,H-5 = 7.3 Hz, CH=CH), 5.55 (t, 1 H, J
H-2
′
,H-1
′ = 9.5 Hz, J
H-2
′
,H-3
′ = 9.5 Hz, H-2¢),
5.30-5.20 (m, 1 H, H-4¢), 5.13 (dd, 1 H, J
H-3
′
,H-2
′ = 10.0 Hz, J
H-3
′
,H-4
′= 3.2 Hz, H-3¢), 4.93 (d, 1 H, J
H-5,H-6 = 7.3 Hz, CH=CH), 4.44 (d, 1 H, J
H-1
′
,H-2
′ = 9.3 Hz, H-1¢), 4.02 (dd, 1 H, J
H-5
′
a,H-5
′
b = 13.2 Hz, J
H-5
′
a,H-4
′ = 2.0 Hz, H-5¢a), 3.80-3.70 (m, 1 H, PrCHN), 3.67 (d, 1 H, J
H-5
′
b,H-5
′
a = 13.2 Hz, H-5¢b), 2.60 (dd, 1 H, J
H-3a,H-3b = 16.6 Hz, J
H-3a,H-2 = 6.3 Hz, CHHC=O), 2.34 (d, 1 H, J
H-3b,H-3a = 16.6 Hz, CHHC=O), 2.00-1.75 [m, 1 H, (CHH)2CH3], 1.65-1.50 (m, 1 H, (CHH)2CH3), 1.30-1.10 (m, 27 H, piv CH3), 0.86 [t, 3 H, J = 7.3 Hz, (CH2)CH
3] ppm. 13C NMR (50.3 MHz, CDCl3): δ = 192.15 (C=O), 177.21, 176.76 (pivC=O), 149.92 (CH=CH), 99.79 (CH=CH), 92.13 (C-1¢), 71.13, 67.97, 66.06 (C-2¢, C-3¢, C-4¢), 66.22 (C-5¢), 53.48 (PrCHN), 38.97 (CH2C=O), 38.89, 38.82, 38.77 (pivCquart.), 32.66 [(CH2)CH3], 27.21, 27.13, 27.02 (piv-CH3), 18.90 [(CH2)CH3], 13.81 [(CH2)CH3] ppm; X-ray analysis: P212121(orthorhombic), a = 9.8895(13) Å, b = 10.1820(11) Å, c = 30.614(4) Å, V = 3082.7(6) Å3, z = 4, F(000) = 1136, CAD4 Enraf Nonius, Cu-Kα, SIR-92, SHELXL-97. Further details of the crystal structure analysis are available on request from the Cambridge Crystallographic Data Centre quoting the deposit number CCDC 229785.
12
Yamamoto Y.
Angew. Chem., Int. Ed. Engl.
1986,
25:
947
13
Gilman H.
Jones RG.
Woods LA.
J. Org. Chem.
1952,
17:
1630
14
Corey EJ.
Boaz W.
Tetrahedron Lett.
1985,
26:
6019
15 X-ray analysis: P1(triclinic), a = 10.1869(6) Å, b = 13.1017(12) Å, c = 15.5126(12) Å, V = 1901.1(3) Å3, z = 2, F(000) = 716, CAD4 Enraf Nonius, Cu-Kα, SIR-92, SHELXL-97. Further details of the crystal structure analysis are available on request from the Cambridge Crystallographic Data Centre quoting the deposit number CCDC 229786.
16 Compound 10: [α]D
25 +11.1 (c 1, EtOH). 1H NMR (200 MHz, DMSO): δ = 9.07 (br s, 1 H, NH), 8.68 (1 H, NH), 3.15-2.80 (m, 2 H, H-1, H-6), 1.90-1.00 (m, 13 H, CH2, CH3), 0.87 [t, 3 H, J = 7.1 Hz, (CH2)2CH
3] ppm. 13C NMR (50.3 MHz, DMSO): δ = 55.98, 52.52 (C-2, C-6), 34.82, 29.78, 27.05, 22.01, 18.75, 17.86 (CH2, CH3), 13.68 [(CH2)2
CH3] ppm.
17
Ciblat S.
Besse P.
Papastergiou V.
Veschambre H.
Canet J.-L.
Troin Y.
Tetrahedron: Asymmetry
2000,
11:
2221 ; and references therein